AIM: To investigate the current @entity298 (PC) management, as well as the usage of @entity1104 ( @entity1104 ) and @entity7730 ( @entity7730 ) in mainland China. METHODS: A potentially curative therapeutic strategy for selecting @entity1 with PC, known as "Techniques", consists of @entity1104 in combination with @entity7730 . A systemic search of published works and clinical trials was performed. Additional papers were retrieved by cross-checking references and obtaining information from Chinese oncologists and relevant conferences. One hundred and one papers and one registered clinical trial on @entity7730 were included. RESULTS: A literature review identified 86 hospitals in 25 out of all 31 areas of mainland China that perform @entity7730 . The earliest report included in our survey was published in 1993. Different approaches to @entity7730 have been utilized, i.e. palliative, prophylactic, and possibly curative treatment. Only one center has consistently performed @entity7730 according to the "Sugarbaker Protocol", which involves evaluating the extent of PC with @entity3906 index and the results of @entity1104 with the completeness of cytoreduction. Positive preliminary results were reported: 7 of 21 @entity1 with PC survived, free of @entity5 , during an 8-43-mo follow-up period. Hyperthermic strategies that include @entity7730 have been practiced for a long time in mainland China, whereas the "Sugarbaker Protocol/Techniques" has been only rarely implemented in China. The Peritoneal Surface Oncology Group International hosts a biannual workshop with the intent to train more specialists in this field and provide support for the construction of quality treatment centers, especially in developing countries like China, whose population is huge and has a dramatically increased incidence of @entity5 . CONCLUSION: To popularize Sugarbaker Protocol/Techniques in mainland China in PC management arising from @entity356 or @entity14 will be the responsibility of the upcoming Chinese Peritoneal Surface Oncology Group.

Hyperthermic intraperitoneal chemotherapy for gastric and XXXX in Mainland China.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'tumors'] @entity3906 :: ('MESH:D010534', 'Disease') :: ['peritoneal cancer'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer'] @entity7730 :: ('MESH:D064146', 'Disease') :: ['hyperthermic intraperitoneal chemotherapy', 'HIPEC'] @entity1104 :: ('MESH:D000267', 'Disease') :: ['CRS', 'cytoreductive surgery'] @entity298 :: ('MESH:D010538', 'Disease') :: ['status of peritoneal carcinomatosis']
@entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer']
